TIRZEPATIDE

---

Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it mimics two naturally occurring hormones involved in blood sugar regulation and appetite control. It was originally developed to support type 2 diabetes management, but it has also shown powerful effects on fat loss and metabolic health.

 Tirzepatide works through two mechanisms:

1. GLP-1 (Glucagon-Like Peptide-1):
   
   • Slows gastric emptying
      
   • Reduces appetite and cravings
      
   • Increases insulin secretion after meals
      

1. GIP (Glucose-Dependent Insulinotropic Polypeptide):
    
   • Enhances insulin response
      
   • Improves fat metabolism
      
   • May enhance the body’s tolerance to higher doses compared to GLP-1 alone
      

The combination provides synergistic metabolic benefits, often outperforming traditional single-pathway GLP-1 medications.

• Supports fat loss and appetite suppression
   
• Improves insulin sensitivity
   
• Enhances glycaemic control
   
• May promote lean muscle preservation during weight loss
   
• Encourages metabolic flexibility and energy balance
   

Weeks 1–4    2.5 mg once weekly

Starting phase to assess tolerance

Weeks 5–8    5.0 mg once weekly

Commonly where mild appetite suppression begins

Weeks 9–12    7.5 mg once weekly

Increased fat-loss activity in research

Weeks 13–16    10 mg once weekly

Typical maintenance phase

Weeks 17–20   12.5 mg once weekly

Optional, depending on research goals

Week 21+   15 mg once weekly (max studied)

High-end dose in clinical studies